GMED icon

Globus Medical

73.39 USD
+0.19
0.26%
At close Apr 1, 4:00 PM EDT
1 day
0.26%
5 days
-4.05%
1 month
-7.39%
3 months
-10.31%
6 months
4.25%
Year to date
-10.31%
1 year
38.13%
5 years
83.80%
10 years
184.46%
0
Funds holding %
of 7,398 funds
0
Analysts bullish %
of 6 analysts

Fund manager confidence

Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)

142% more first-time investments, than exits

New positions opened: 104 | Existing positions closed: 43

110% more call options, than puts

Call options by funds: $24.5M | Put options by funds: $11.7M

16% more capital invested

Capital invested by funds: $7.79B [Q3] → $9.01B (+$1.22B) [Q4]

11% more funds holding

Funds holding: 443 [Q3] → 493 (+50) [Q4]

6% more funds holding in top 10

Funds holding in top 10: 18 [Q3] → 19 (+1) [Q4]

10% more repeat investments, than reductions

Existing positions increased: 166 | Existing positions reduced: 151

0.67% less ownership

Funds ownership: 96.38% [Q3] → 95.7% (-0.67%) [Q4]

Research analyst outlook

6 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target
$82
12%
upside
Avg. target
$95
29%
upside
High target
$103
40%
upside

6 analyst ratings

positive
67%
neutral
33%
negative
0%
Truist Securities
Richard Newitter
51% 1-year accuracy
22 / 43 met price target
12%upside
$82
Hold
Maintained
18 Mar 2025
Barclays
Matt Miksic
59% 1-year accuracy
24 / 41 met price target
40%upside
$103
Overweight
Maintained
24 Feb 2025
Stifel
Mathew Blackman
24% 1-year accuracy
4 / 17 met price target
28%upside
$94
Buy
Maintained
21 Feb 2025
Wells Fargo
Vik Chopra
36% 1-year accuracy
4 / 11 met price target
27%upside
$93
Overweight
Maintained
21 Feb 2025
Canaccord Genuity
William Plovanic
46% 1-year accuracy
22 / 48 met price target
38%upside
$101
Buy
Maintained
10 Jan 2025

Financial journalist opinion

Based on 10 articles about GMED published over the past 30 days

Neutral
Business Wire
1 week ago
NEVRO INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Nevro Corp. - NVRO
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Nevro Corp. (NYSE: NVRO) to Globus Medical, Inc. (NYSE: GMED). Under the terms of the proposed transaction, shareholders of Nevro will receive $5.85 in cash for each share of Nevro that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or w.
NEVRO INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Nevro Corp. - NVRO
Positive
Zacks Investment Research
1 week ago
GMED Stock Jumps 41.8% in a Year: What's Behind the Rally?
Globus Medical's robust musculoskeletal offerings and synergies from the NuVasive merger are fueling its stock gains.
GMED Stock Jumps 41.8% in a Year: What's Behind the Rally?
Positive
Zacks Investment Research
1 week ago
Should You Hold Globus Medical Stock in Your Portfolio Now?
GMED stays on investors' radar due to its high NuVasive-merger synergies and solid Musculoskeletal prospects.
Should You Hold Globus Medical Stock in Your Portfolio Now?
Positive
Zacks Investment Research
2 weeks ago
New Product Launches Benefit GMED Stock Amid Macro Issues
Globus Medical currently awaits a strong cadence of product launches throughout the Musculoskeletal portfolio in the coming months of 2025.
New Product Launches Benefit GMED Stock Amid Macro Issues
Positive
Zacks Investment Research
2 weeks ago
Globus Medical Expands Anterior Spine Portfolio With Two New Offerings
GMED announces the commercial launch of COHERE ALIF Spacer and Modulus ALIF Blades.
Globus Medical Expands Anterior Spine Portfolio With Two New Offerings
Neutral
GlobeNewsWire
3 weeks ago
Globus Medical extends versatility of Advanced Materials Science™ anterior interbody portfolio with launch of COHERE™ ALIF Spacer and Modulus™ ALIF Blades
AUDUBON, Pa., March 11, 2025 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal technology company, today announced two commercial launches: COHERE™ ALIF Spacer: The first Porous PEEK™ interbody spacer for anterior lumbar interbody fusion (ALIF) surgery, and Modulus™ ALIF Blades: An extension of the market-leading Modulus™ ALIF interbody spacer system.
Globus Medical extends versatility of Advanced Materials Science™ anterior interbody portfolio with launch of COHERE™ ALIF Spacer and Modulus™ ALIF Blades
Neutral
GlobeNewsWire
3 weeks ago
Globus Medical to feature ExcelsiusFlex™ for Total Knee Arthroplasty at the American Academy of Orthopedic Surgeons Annual Meeting
AUDUBON, Pa., March 06, 2025 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal technology company, today announced it will participate in the 2025 Annual Meeting of the American Academy of Orthopedic Surgeons (AAOS) in San Diego, Calif., from March 10-14, 2025.
Globus Medical to feature ExcelsiusFlex™ for Total Knee Arthroplasty at the American Academy of Orthopedic Surgeons Annual Meeting
Neutral
GlobeNewsWire
3 weeks ago
Globus Medical to participate in the Canaccord Genuity 2025 Musculoskeletal Conference
AUDUBON, Pa., March 05, 2025 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal technology company, today announced it is scheduled to participate in the Canaccord Genuity 2025 Musculoskeletal Conference in San Diego.
Globus Medical to participate in the Canaccord Genuity 2025 Musculoskeletal Conference
Neutral
Zacks Investment Research
3 weeks ago
Is the Options Market Predicting a Spike in Globus Medical (GMED) Stock?
Investors need to pay close attention to Globus Medical (GMED) stock based on the movements in the options market lately.
Is the Options Market Predicting a Spike in Globus Medical (GMED) Stock?
Neutral
PRNewsWire
3 weeks ago
Nevro Reports Fourth-Quarter and Full-Year 2024 Financial Results
REDWOOD CITY, Calif. , March 4, 2025 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today reported its fourth-quarter and full-year 2024 financial results.
Nevro Reports Fourth-Quarter and Full-Year 2024 Financial Results
Charts implemented using Lightweight Charts™